

***Explanation of Conflict of Interest Disclosure Parts:***

**Part One:** All Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical companies doing business with or proposing to do business with ACNP over past 2 years (Jan. 2011-Present)

**Part Two:** Income Sources & Equity of \$10,000 or greater

**Part Three:** Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP which constitutes more than 5% of personal income (Jan. 2011-Present):

**Part Four:** Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products directly, or indirectly through a foundation, university, or any other organization (Jan. 2011-Present)

**Part Five:** My primary employer is a pharmaceutical/biotech/medical device company.

**ACNP 2013 Council Disclosures**

**John Csernansky:** *Part 1:* Eli Lilly & Company, Sanofi-Aventis

**Ronald Duman:** *Part 1:* Bristol Myers Squibb, Eli Lilly & Company, Forest, Johnson & Johnson, Lundbeck, Pfizer; *Part 4:* Eli Lilly & Company, Lundbeck, Johnson & Johnson, Forest

**Alan Frazer:** *Part 1:* Lundbeck, Cyberonics, Takeda, Eli Lilly & Company; *Part 4:* Lundbeck

**Suzanne Haber:** *Part 1:* Medtronic, Inc., Pfizer

**John Krystal:** *Part 1:* AbbVie, Inc., AMGEN, Astra Zeneca, Biological Psychiatry, Bristol-Myers Squibb, Eli Lilly and Co. Otsuka Pharmaceutical Development & Commercialization, Quintiles Consulting, Sage Therapeutics, Inc., Shire Pharmaceuticals, Sunovion Pharmaceuticals, Inc., Takeda Industries, Teva Pharmaceutical Industries, Ltd.; *Part 2:* Biological Psychiatry Editor; *Part 4:* Janssen Research Foundation Patents and Inventions

1) Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. Patent #:5,447,948. September 5, 1995

2) Vladimir, Coric, Krystal, John Hm, Sanacora, Gerard – Glutamate Agents in the Treatment of Mental Disorders No. 11/399,188 April 5, 2006 (Pending)

3) Intranasal Administration of Ketamine to Treat Depression (pending)

**David Kupfer:** *Part 1:* Sevier (spouse), Guilford Press (spouse); *Part 2:* American Psychiatric Association, Sevier (spouse)

**David Lewis:** *Part 1:* Bristol-Myers Squibb, Concert; *Part 4:* Bristol-Myers Squibb Foundation, Bristol-Myers Squibb, Curridium Ltd, Pfizer

**Robert Malenka:** *Part 1:* Circuit Therapeutics, Inc.; *Part 2:* Circuit Therapeutics, Inc.

**Eric Nestler:** *Part 1:* PsychoGenics, Berg Pharma, Merck Research Laboratories, Johnson & Johnson; *Part 2:* PsychoGenics, Berg Pharma, Merck Research Laboratories; *Part 3:* Berg Pharma, Merck Research Laboratories; *Part 4:* Johnson & Johnson

**Council Members with No Disclosures**

Karen Berman  
Linda Brady  
Barry Everitt, Council-Elect  
Peter Kalivas  
Marina Wolf, Council-Elect  
Ronnie Wilkins, Executive Director

**2013 Program Committee Disclosures**

**Anissa Abi-Dargham:** *Part 1:* Otsuka, Shire, Roche, BMS, Pfizer, Takeda, Amgen, Forest, Pierre Fabre, *Part 4:* Pierre Fabre, Forest

**Randy Blakely:** *Part 1:* Lundbeck Amgen, *Part 4:* Amgen

**Ariel Deutch:** *Part 1:* Eli Lilly

**Paul Kenny:** *Part 1:* Eolas Therapeutics

**Henry Kranzler:** *Part 1:* Lundbeck, Pfizer, Lilly Consultant: Alkermes, Lundbeck, Roche *Part 2:* Lundbeck, *Part 4:* Pfizer

**Pat Levitt:** *Part 1:* Scientific Advisory Board for Pediatric Biosciences

**Stephen Marder:** *Part 1:* Abbott, Roche, Genentech, Otsuka, Shire, EnVivo, Targacept, Pfizer, Lundbeck, Bristol Meyers Squibb., *Part 4:* Sunovion, Novartis, Amgen, Psychogenics

**Barbara Mason:** *Part 1:* Johnson & Johnson Pharmaceutical Research & Development, LLC, Lohocla Research Corporation; Arkeo Pharmaceuticals, Inc., Addex Pharmaceuticals; *Part 4:* Corcept.

**Daniel Mathalon:** *Part 1:* I am a consultant for Bristol-Myers Squibb I am a consultant for Amgen, *Part 4:* 2011-AstraZeneca investigator initiated grant

**Colleen McClung:** *Part 1:* I received honorarium for a seminar given at Johnson & Johnson in 2012. , *Part 4:* I received a grant from IMHRO partnered with Johnson & Johnson in 2012 (Rising Star Translational Research Award).

**Kalpana Merchant:** *Part 5:* Eli Lilly and Company

**Andreas Meyer-Lindenberg:** *Part 1:* Speaker and Advisory boards: AstraZeneca, J+J, Lundbeck, Servier, Lilly

**Lisa Monteggia:** *Part 1:* Speaker's bureau, Roche.

**Akira Sawa:** *Part 4:* Astellas Pharm., Dainippon Sumitomo, Mitsubishi-Tanabe Pharm., Takeda, Johnson and Johnson, Asubio, Sucampo, Eli Lilly, Taisho, Pfizer, Afraxis, Sanofis-Aventis

**Darryle Schoepp:** *Part 1:* Merck and Company, Inc., *Part 2:* Merck and Company, Inc., *Part 3:* Merck and Company, Inc., *Part 4:* Merck and Company, Inc., *Part 5:* Merck and Company, Inc.

**Thomas Schulze:** *Part 1:* Almirall (Neurofarmagen/genetic testing)

**Pamela Sklar:** *Part 4:* Sage BioNetworks

**Matthew State:** *Part 1:* Pfizer pharmaceuticals SynapDx, *Part 2:* Pfizer pharmaceuticals

**Trisha Suppes:** *Part 1:* Sunovion Pharmaceuticals Inc, Jones and Bartlett, *Part 4:* AstraZeneca, National Institute of Mental Health, Pfizer, Inc., Sunovion Pharmaceuticals Inc., Elan Pharma International Limited, and VA Cooperative Studies Program.

**Audrey Tyrka:** *Part 1:* Medtronic, Neuronetics, NeoSync, *Part 4:* Medtronic, Neuronetics, NeoSync

**Jeremy Veenstra-VanderWeele:** *Part 1:* Novartis, Seaside Therapeutics, Roche Pharmaceuticals, Forest, SynapDx.

**Daniel Weinberger:** *Part 1:* AstraZeneca, Johnson & Johnson, Lundbeck, Servier, and Lilly

**Carlos Zarate:** *Part 1:* co-inventor - patent application for the use of ketamine and its metabolites in major depression. Patent rights assigned to U.S. government; will receive a percentage of any royalties received by the government.

## **NOTHING TO DISCLOSE**

Ted Abel

Gary Aston-Jones

Hilary Blumberg

John Bruno

Kristin Cadenhead

Joe Callicott

Stephen Deutsch

Rita Goldstein

David Grandy  
Robert Greene  
Kalpana Merchant  
Karoly Mirnics  
Bitá Moghaddam  
Uma Rao  
Kerry Ressler  
John Rubenstein  
Etienne Sibille  
Arielle Stanford  
James Sutcliffe  
Rachel Yehuda

### ACNP 2013 Presenter Disclosures

**Abel, Ted** : *Part 2*: Editor, Neurobiology of Learning and Memory, Elsevier

**Abi-Dargham, Anissa**: *Part 1*: Pierre Fabre, Pfizer, Takeda, Otsuka, Amgen, Roche, *Part 4*: Pierre Fabre

**Alexopoulos, George**: *Part 1*: I have a research grant from Forest; have consulted for Hoffman-LaRoche, Janssen, Lilly, Navidea, Pfizer, and Otsuka; and have been on speakers' bureaus for Astra Zeneca, Avanir, Merck, Novartis, and Sunovion., *Part 2*: Astra Zeneca, Forest, Merck, Sunovion, *Part 4*: I have received grant support from Forest

**Alphs, Larry**: *Part 1*: Janssen Scientific Affairs Employment and Stock, *Part 2*: 2011-2013 Employed by Janssen Scientific Affairs a division of Johnson & Johnson; I also received stock from them., *Part 3*: Janssen Scientific Affairs, *Part 4*: None, *Part 5*: Johnson & Johnson

**Appelbaum, Paul**: *Part 1*: Equity interest in COVR, Inc. (violence prediction software)., *Part 2*: Professor, Columbia University, Research Scientist, NY State Psychiatric Institute, Private practice of general and forensic psychiatry

**Arnsten, Amy**: *Part 1*: I have recently had conversations with Pfizer, Merck, Shire and Evotec, and received a small grant from Pfizer to perform physiological assessments of one of their compounds in primate prefrontal cortex. *Part 2*: *Yale University and I receive royalties from the sales of Intuniv from Shire Pharmaceuticals.*

**Banks, Matthew**: *Part 1*: Collaborator on a grant from Perdue Pharmaceuticals related to opioid pharmacology in nonhuman primates. , *Part 4*: Collaborator on a grant from Perdue Pharmaceuticals related to opioid pharmacology in nonhuman primates.

**Baram, Tallie Z.**: *Part 1*: Baram's institution (UCI) received travel & consultanship; Questcor, *Part 2*: stock ownership, TEVA

**Barch, Deanna:** *Part 1:* Consultant for Pfizer and Amgen, Research Grants from Novartis and Dainippon Sumitomo Pharma Co., Ltd, *Part 4:* Research Grants from Novartis and Dainippon Sumitomo Pharma Co., Ltd

**Becker, Howard:** *Part 1:* Dr. Becker has conducted contractual work and served as a consultant for Eli Lilly and Company, but those activities have no relationship to work that will be presented in this symposium., *Part 4:* Dr. Becker engaged in a research contract with Eli Lilly and Company.

**Bergen, Andrew :** *Part 1:* Dr. Bergen has had research supported by an Agreement with Perlegen Biosciences, by an Agreement with Medco Health Solutions, and with loans of equipment and reagents from Affymetrix and from Genisphere.

**Bikson, Marom:** *Part 1:* Marom Bikson has equity in Soterix Medical Inc., *Part 4:* Marom Bikson received grant support from Soterix Medical Inc.

**Blennow, Kaj:** *Part 1:* Innogenetics, Kyowa Kirin Pharma, Roche, Pfizer, BMS.

**Blier, Pierre:** *Part 1:* I participated in advisory boards, gave presentations, and/or received research grants (without a salary portion and administered by my institution) from Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Forest, Lundbeck, Merck, Otsuka, Pfizer, Roche, Takeda, and Servier

**Boettiger, Charlotte:** *Part 1:* I own shares in the following companies: Becton Dickinson Co., Bio Rad Laboratories Inc. CL A, Sigma Aldrich Corp., Thermo Fisher Scientific Inc. , *Part 2:* Becton Dickinson Co., Sigma Aldrich Corp.

**Brandon, Nicholas:** *Part 1:* AstraZeneca, *Part 2:* AstraZeneca, *Part 3:* AstraZeneca, *Part 5:* AstraZeneca.

**Buchanan, Robert:** *Part 1:* Advisory Boards: Abbott; Amgen; Janssen Pharmaceutical, Inc.; NuPathe; Pfizer; Roche; Takeda, Consultant: Abbott; Amgen; Bristol-Myers Squibb; EnVivo; Omeros; Pfizer, DSMB: Otsuka; Pfizer

**Bustillo, Juan:** *Part 1:* Speakers Bureau and advisory consulting for Otsuka America Pharmaceutical Inc

**Carlezon, William:** *Part 1:* I am a consultant for Concert Pharmaceuticals. My spouse is a full-time employee of EMD Serono., *Part 2:* My spouse is a full-time employee of EMD Serono., *Part 3:* My spouse is a full-time employee of EMD Serono.

**Carter, Cameron:** *Part 1:* Grant funding from GSK 2011, *Part 4:* GSK 2011

**Casey, Daniel:** *Part 1:* Consultant/advisory board: Bristol-Myers Squibb, Genentech and Merck; Speaker's bureau: Bristol-Myers Squibb, Merck and Sunovion

**Chappell, Phillip:** *Part 1:* ., *Part 5:* Pfizer Inc

**Charney, Dennis:** *Part 1:* Dr. Charney has been named as inventors on a pending use-patent of ketamine for the treatment of depression. If ketamine were shown to be effective in the treatment of depression

and received approval from the Food and Drug Administration for this indication, Dr. Charney and Mount Sinai School of Medicine could benefit financially.,

**Coccaro, Emil:** *Part 1:* Scientific Advisory Board for Azivan Pharmaceuticals.

**Correll, Christoph:** *Part 1:* Dr. Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza; Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Lundbeck, Merck, Janssen/J&J, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda. He has received grant support from BMS, Janssen/J&J, and Otsuka. , *Part 2:* Bristol-Myers Squibb, Cephalon, Merck, Otsuka, Pfizer, ProPhase., *Part 4:* BMS, Janssen/J&J, and Otsuka

**Cross, Alan:** *Part 5:* Current employee of AstraZeneca Pharmaceuticals, in Wilmington DE, the company that sponsored/funded the study reported here.

**Dalmau, Josep:** *Part 1:* JD receives royalties from Athena Diagnostics for a patent for the use of Ma2 as an autoantibody test, and licensing fees from Euroimmun for a patent for the use of NMDAR as an autoantibody test.

**Daskalakis, Zafiris:** *Part 1:* Received external funding through Neuronetics and Brainsway Inc. ZJD has also served on the advisory board for Hoffmann-La Roche Limited. This work was supported by the Ontario Mental Health Foundation (OMHF), the Canadian Institutes of Health Research (CIHR), the Brain and Behaviour Research Foundation and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute., *Part 4:* Brainsway Inc.

**Davis, Kenneth:** *Part 1:* My wife, Bonnie M. Davis, MD is a patent holder on the use patent for galantamine for Alzheimer's disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson. She receives royalty income from this license.,*Part 2:* My wife, Bonnie M. Davis, MD is a patent holder on the use patent for galantamine for Alzheimer's disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson. She receives royalty income from this license., *Part 3:* My wife, Bonnie M. Davis, MD is a patent holder on the use patent for galantamine for Alzheimer's disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson. She receives royalty income from this license.

**de Wit, Harriet:** *Part 1:* I conducted a research study funded by Unilever in 2011.

**Dourish, Colin:** *Part 1:* Employee, Director and shareholder of P1vital, *Part 2:* Employee, Director and shareholder of P1vital, *Part 3:* Employee, Director and shareholder of P1vital, *Part 5:* P1vital

**Dubocovich, Margarita:** *Part 1:* Takeda Pharmaceuticals North America Inc

**Duman, Ronald:** *Part 1:* Lilly, Forest, Bristol Myers Sqibb, Taisho, Johnson & Johnson, Pfizer, Lundbeck, *Part 4:* Lilly, Forest, Lundbeck, Johnson & Johnson

**Duncan, Erica:** *Part 4:* Grant support from Brain Plasticity, Inc.

**Elliott, Mark:** *Part 4:* The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Evins, A. Eden:** *Part 1:* Pfizer: Supplemental research support for the NIDA funded trial: R01 DA021245 Extended Duration Varenicline for Prevention of Smoking in Schizophrenia, Envivo Pharmaceuticals: Supplemental research support for the NIDA funded R01 DA030992 Proof of Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence, GSK: Supplemental research support for NIDA funded U01 DA019378 Cooperative Drug Discovery Group for Nicotine Dependence, *Part 4:* Pfizer: Supplemental research support for the NIDA funded trial: R01 DA021245 Extended Duration Varenicline for Prevention of Smoking in Schizophrenia, Envivo Pharmaceuticals: Supplemental research support for the NIDA funded R01 DA030992 Proof of Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence, GSK: Supplemental research support for NIDA funded U01 DA019378 Cooperative Drug Discovery Group for Nicotine Dependence

**Fan, Xiaoduo:** *Part 1:* Eli Lilly - advisory board, *Part 4:* Eli Lilly - investigator initiated clinical trial grant

**Fava, Maurizio:** *Part 1:* Advisory/Consulting: Abbott Laboratories; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Bayer AG; Best Practice Project Management, Inc.; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Neuralstem, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG; NuPathe; Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Otsuka Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite® LLC.; PharmorX Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc.; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; Teva; Transform Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc.; Speaking/Publishing: Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource, Corp.; Wyeth-Ayerst Laboratories; Equity Holdings: Compellis; PsyBrain, Inc.; Royalty/patent, other income:

Patent for Sequential Parallel Comparison Design (SPCD), which are licensed by MGH to RCT Logic, LLC; and patent application for a combination of azapirones and bupropion in Major Depressive Disorder (MDD).; Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; World Scientific Publishing Co. Pte.Ltd. , *Part 2*: Belvoir Media Group for editing a newsletter: 2011-\$12,000., *Part 4*: Abbott Laboratories; Alkermes, Inc.; Aspect Medical Systems; AstraZeneca; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Clintara, LLC; Covance; Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; GlaxoSmithKline; Icon Clinical Research; i3 Innovus/Ingenix; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; NARSAD; NCCAM; NIDA; NIMH; Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmavite® LLC; Photothera; Roche; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst Laboratories

**Fleischhacker, W. Wolfgang** : *Part 1*: Amgen, Lundbeck, Roche, Bristol-Myers Squibb, Otsuka, Janssen, MedAvante, Merck, Vanda, Endo, Takeda, Pfizer, Reckitt-Benckiser, *Part 3*: Janssen, Otsuka, Reckitt-Benckiser

**Foster, Marc**: *Part 1*: Daktari Diagnostics, Inc., Visionscope Technologies, LLC, ImaCor, LLC, *Part 5*: Transparency Life Sciences, LLC

**Frail, Donald**: *Part 1*: I am an employee of AstraZeneca. , *Part 2*: I am an employee of AstraZeneca. , *Part 3*: I am an employee of AstraZeneca and was an employee of Pfizer. , *Part 5*: I am an employee of AstraZeneca.

**Gainetdinov, Raul**: *Part 4*: I have research grants from F. Hoffmann La-Roche (Basel, Switzerland) on the topic of this presentation.

**George, Tony**: *Part 1*: Grant support from Pfizer, Speakers Bureau Pfizer, 2011 and 2012, Data Monitoring Committee, Novartis, 2011-present, *Part 4*: Pfizer - for studies of varenicline in smokers with mental illness, including schizophrenia

**Geyer, Mark**: *Part 1*: Consulting compensation from Abbott, Acadia, Addex, Cerca, Lundbeck, Merck, Neurocrine, Omeros, San Diego Instruments , Takeda, DART and Teva, *Part 2*: Equity interest in San Diego Instruments, *Part 3*: Equity interest in San Diego Instruments, *Part 4*: Research grant support from Intracellular Therapeutics, Johnson & Johnson, NIDA, NIMH, and the U.S. Veteran's Administration VISN 22 Mental Illness Research, Education, and Clinical Center.

**Glatt, Stephen**: *Part 1*: I serve as a scientific consultant to SynapDx Corp.

**Gobbi, Gabriella**: *Part 1*: Lilly, Astra-Zeneca, Lundbeck, Cosmas Therapeutics

**Goff, Donald**: *Part 1*: DSMB member: Otsuka Pharmaceuticals, *Part 4*: PamLab, Pfizer, Novartis, GSK



**Gold, Lisa:** *Part 1:* Full-time employee of Merck and Co, Inc, *Part 2:* Full-time employee of Merck and Co, Inc, *Part 3:* Full-time employee of Merck and Co, Inc, *Part 5:* Full-time employee of Merck and Co, Inc

**Gopal, Srihari:** *Part 2:* Shareholder Johnson & Johnson (JNJ), Shareholder Merck (MRK), *Part 5:* Full time employee Johnson & Johnson (JNJ)

**Gordon, Joshua:** *Part 1:* Speaker at Pfizer Basic Research Division Neuroscience Symposium, honorarium, 2011,

**Gründer, Gerhard:** *Part 1:* Dr. Gründer has served as a consultant for Bristol-Myers Squibb (New York, NY), Cheplapharm (Greifswald, Germany), Eli Lilly (Indianapolis, Ind), Forest Laboratories (New York, NY, USA), Lundbeck (Copenhagen, Denmark), Otsuka (Rockville, Md.), Roche (Basel, Switzerland), and Servier (Paris, France). He has served on the speakers' bureau of Bristol-Myers Squibb, Eli Lilly, Gedeon Richter (Budapest, Hungary), Otsuka, Roche, and Servier. He has received grant support from Alkermes, Eli Lilly, and Roche. He is co-founder of Pharma-Image – Molecular Imaging Technologies GmbH, Düsseldorf. , *Part 2:* 2011: Eli Lilly, *Part 3:* 2011: Eli Lilly, *Part 4:* Dr. Gründer has received grant support from Alkermes, Eli Lilly, and Roche. He is co-founder of Pharma-Image – Molecular Imaging Technologies GmbH, Düsseldorf.

**Grace, Anthony :** *Part 1:* Johnson & Johnson, Lundbeck, Pfizer, GSK, Puretech Ventures, Merck, Takeda, Dainippon Sumitomo, Otsuka, Lilly, Roche, Asubio, *Part 4:* Lilly, Lundbeck

**Graham, Danielle:** *Part 5:* I am a full time employee of EMD Serono Research & Development Institute.

**Greenberg, Benjamin:** *Part 1:* Meeting Travel Expense, Medtronic Inc, *Part 4:* Research Grant Support, Hoffman-LaRoche, Inc.

**Greist, John :** *Part 1:* I do not believe questions 2 and 4 are applicable because I do not know whether any/all of the companies with which I do business are "doing business with or proposing to do business with ACNP" and find that matter confusing. , *Part 2:* eResearch Technology, Healthcare Technology Systems, Possibly Pfizer, though I expect something less than \$10,000., If I own any stock in any pharmaceutical or device company it would be in retirement accounts such as the State of Wisconsin Retirement Plan over which I have no control. I have never purchased or held any pharmaceutical stocks in my personal investment account, nor has my spouse., *Part 3:* Please see #2 above., *Part 4:* AstraZeneca, eResearch Technology, Forest, Lilly, Novo Nordisk, Otsuka, Pfizer, Takeda, Transcept, UCB, *Part 5:* Healthcare Technology Systems is a medical assessment company. Though it is not technically a pharmaceutical/biotech/medical device company, I list it here to avoid any possible misunderstanding.

**Gur, Raquel:** *Part 4:* The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Gur, Ruben:** *Part 4:* The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Gurney, Mark:** *Part 1:* Dr. Gurney is an employee of Tetra Discovery Partners., *Part 2:* Dr. Gurney is an employee of Tetra Discovery Partners., *Part 3:* Dr. Gurney is an employee of Tetra Discovery Partners., *Part 5:* Tetra Discovery Partners.

**Haber, Suzanne:** *Part 1:* Dr. Haber has received consultation fees from Medtronic, Inc and Pfizer, Inc.

**Harrison, Paul :** *Part 1:* Advisory board, Sunovion (2013), Honorarium for educational talks, Otsuka (2013), *Part 2:* Employment: University of Oxford, Expert witness work for Pinsent Masons, London, Deputy Editor Honorarium, Biological Psychiatry, *Part 4:* Unrestricted educational grant from Takeda (Cambridge) 2012-13

**Hasler, Gregor :** *Part 1:* Servier (Suisse) SA , Lundbeck (Schweiz) AG, Schweizerische Gesellschaft für Bipolare Störungen, AstraZeneca, Eli Lilly (Suisse) SA , *Part 4:* Novartis Switzerland

**Hen, Rene:** *Part 1:* Serve on Scientific Advisory Boards for Roche Pharmaceuticals, Lundbeck and Servier

**Heres , Stephan :** *Part 1:* I have received honoraria from Janssen-Cilag, Eli Lilly, Sanofi-Aventis and Johnson & Johnson. , I have accepted travel or hospitality payment from Janssen-Cilag, Sanofi-Aventis, Johnson & Johnson, Pfizer, Bristol-Myers-Squibb, AstraZeneca, Lundbeck, Novartis and Eli Lilly. , I have participated in clinical trials sponsored or supported by Eli Lilly, Janssen Cilag, Johnson & Johnson, Bristol-Myers-Squibb, AstraZeneca, Lundbeck, Novartis, Servier, Pierre Fabre, Pfizer, Organon, Roche and Merck. , I have participated in advisory activities and boards for Janssen, Johnson & Johnson, Eli Lilly, Lundbeck and Roche.

**Hermanson, Daniel :** *Part 1:* DJH, LJM and SP have submitted a patent application entitled "Compositions and Methods for Substrate-Selective Inhibition of Endocannabinoid Oxygenation," which includes the compound LM-4131.

**Hickie, Ian:** *Part 1:* Servier, Astrazeneca, Pfizer, Janseen, Eli lilly , *Part 4:* Servier Laboratories

**Higgs, Suzanne:** *Part 1:* Academic Supervisor of PhD studentship part funded by P1vital, *Part 4:* Academic Supervisor of PhD studentship part funded by P1vital

**Hollander, Eric:** *Part 1:* research grants: Simons Foundation, Roche, Transcept, Forest, Coronado Biosciences, consultant: Roche, Coronado Biosciences, *Part 4:* research grants: Simons Foundation, Roche, Transcept, Forest, Coronado Biosciences,

**Hyman, Steven:** *Part 1:* Member - Novartis Science Board, Consultant - AstraZeneca, iMed, Scientific Advisory Board - Fidelity Biosciences, *Part 2:* Novartis Science Board, Scientific Advisory Board - Fidelity Biosciences

**Innis, Robert:** *Part 1:* Eli Lilly has provide funds to NIMH to support my research., *Part 4:* Eli Lilly has provide funds to NIMH to support my research.

**Iosifescu, Dan:** *Part 1:* In the previous 36 months, Dr. Iosifescu has received research funding through Mount Sinai School of Medicine from AstraZeneca, Brainsway, Euthymics, Neosync, and Roche; he has received consulting fees from CNS Response, Otsuka, Servier and Sunovion., *Part 4:* In the previous 36 months, Dr. Iosifescu has received research funding through Mount Sinai School of Medicine from AstraZeneca, Brainsway, Euthymics, Neosync, and Roche; he has received consulting fees from CNS Response, Otsuka, Servier and Sunovion.

**Jarskog, Lars:** *Part 1:* Research grants from Sunovion, Amgen, Roche. DSMB board member - Janssen.

**Javitt, Daniel:** *Part 1:* Honoraria from Sunovion, BMS, Eli Lilly, Takeda, Omeros, Otsuka, Consensus Medical Communications, Guidepoint global, American Capital, Clearpoint communications, Vindico Medical Communication, and Clearview Healthcare. Research support from Pfizer and Roche; equity in, Glytech, Inc. and AASI; intellectual property rights for use of glycine, D-serine and glycine transport inhibitors in schizophrenia, and serves, on the advisory board of Promentis., *Part 2:* Columbia, NYS OMH, Glytech, *Part 4:* Pfizer, Roche

**Kalin, Ned:** *Part 1:* Honorariums: CME Outfitters, Elsevier, Letters & Sciences; Scientific Advisory Board, Corcept Therapeutics, Neuronetics, CeNeRx BioPharma, Neurocrine Biosciences, Neuronetics, LLC, Medivation, Janssen; Stockholder, Equity Options, Corcept Therapeutics, CeNeRx BioPharma; Owner, Promoter Neurosciences, LLC; Patents, Promoter sequences for corticotropin-releasing factor CRF2alpha and method of identifying agents that alter the activity of the promoter sequences: U.S. Patent issued on 07-04-06; patent #7071323, U.S. Patent issued on 05-12-09; patent #7,531,356, Promoter sequences for urocortin II and the use thereof: U.S. Patent issued on 08-08-06; patent #7087385, Promoter sequences for corticotropin-releasing factor binding protein and use thereof: U.S. Patent issued on 10-17-06; patent #7122650, *Part 2:* Elsevier, *Part 4:* Project Investigator: Neurobehavioral Bases of Emotion Regulation and Dysregulation in Adolescence. P50 MH84051, National Institute of Mental Health/National Institute of Health, \$234,757,00 2008-2013, Principal Investigator: Developmental Mechanisms Underlying the Risk to Develop Anxiety and Depression. Subproject on a Silvio O. Conte Center for Interdisciplinary Research on Brain, Behavior & Mental Health, National Institute of Mental Health, \$1,855,782, 2008-2013, Principal Investigator: Development and regulation of emotion in primates. R01 MH046729, National Institute of Mental Health/National Institute of Health, \$425,841.00, 2012-2017, Principal Investigator: Brain mechanisms underlying childhood anxiety. R21MH092581, National Institute of Mental Health/National Institute of Health, \$125,000, 2012-2014, Principal Investigator: Brain Mechanisms Mediating Genetic Risk Factors for Anxiety and Depression. DHHS, PHS R01 MH081884. National Institute of Mental Health, \$4,472,284, 2008-2012, Principal Investigator: Defining corticotropin-releasing factor (CRF) system changes in amygdala and medial temporal cortex in association with depression and suicide. The Stanley Medical Research Institute, \$150,000, 2009-2011, Principal Investigator: Development and Regulation of Emotion in Primates. R01 MH046729, National Institute of Mental Health, \$2,743,637, 2005-2011, Principle Investigator: Combining mouse and monkey models to understand human risk for psychopathology. MH091550 . National Institute of Mental Health, \$275,000, 2010-2012, Co-Principal Investigator: Neural Substrates of Affective Style and Emotion Regulation. R01, MH043454, National Institute of Mental Health, \$150,000 Supplement, 2008-2011, APIRE/Janssen Resident Psychiatric Mentor Grant,

**Kantrowitz, Joshua:** *Part 1:* Dr. Kantrowitz reports having received consulting payments within the last 2 years from Otsuka Pharmaceuticals, Quadrant Health, RTI Health solutions, the Healthcare Advisory Board, Vindico Medical Education, Health Advances, LLC, Strategic Edge Communications. He owns a small number of shares of common stock in GlaxoSmithKline., *Part 2:* NYS OMH, Columbia, RFMH, St Luke's-Roosevelt, *Part 4:* He has conducted clinical research supported by the NIMH, the Stanley Foundation, Roche-Genetech, EnVivo, Psychogenics, Sunovion, Novartis, Pfizer, Lilly and GlaxoSmithKline.

**Kenny, Paul :** *Part 1:* Consultant to Pfizer, Inc., Co-founder of Eolas Therapeutics.

**Kinon, Bruce:** *Part 1:* Employee of Eli Lilly and Company, Shareholder of Eli Lilly and Company, *Part 2:* Employee of Eli Lilly and Company, Shareholder of Eli Lilly and Company, *Part 3:* Employee of Eli Lilly and Company, *Part 5:* Employee of Eli Lilly and Company

**Klann, Eric:** *Part 1:* I am a consultant for Takeda Pharmaceuticals. My wife is employed by Takda Pharmaceuticals., *Part 2:* Consultant for Takeda Pharmaceuticals., *Part 3:* Consultant for Takeda Pharmaceuticals during sabbatical of 2012-13 academic year.

**Knight, Scott:** *Part 5:* Sigma Aldrich

**Kohler, Christian:** *Part 4:* The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Koob, George:** *Part 1:* Addex Pharmaceuticals, Psychogenics Inc., Arkeo Inc., Embera Inc, Casa Palmera Treatment facility, *Part 2:* Casa Palmera treatment facility

**Krystal, John:** *Part 1:* Abbott, Amgen, AstraZeneca, BMS, Eisai, Estellas, Forest, Johnson and Johnson, Lilly, Lohocla, Mnemosyne, Naurex, Novartis, Pfizer, Shire, Sunovion, Takedam, Teva, *Part 4:* AstraZeneca, Pfizer

**Lanz, Thomas:** *Part 1:* Employee of Pfizer, *Part 3:* Employee of Pfizer, *Part 5:* Pfizer

**Lapidus, Kyle:** *Part 1:* Dr. Lapidus has received support for this project from the Brain and Behavior Research Foundation's Young Investigator Award and Apire Janssen Psychiatric Resident Research Scholars Award and serves as scientific advisor for Halo Neuro, Inc. He also participated in an interview on the future of antidepressants with LCN Consulting, Inc., *Part 4:* Dr. Lapidus has received support for this project from the Brain and Behavior Research Foundation's Young Investigator Award and Apire Janssen Psychiatric Resident Research Scholars Award.

**Lavretsky, Helen:** *Part 1:* Rsearch grants from Forest Research Institute and Alzheimer's Research and Prevention foundation, *Part 2:* None, *Part 3:* None, *Part 4:* Forest Research Institute- research grants

**Lisanby, Sarah:** *Part 4:* Research Grants to my institution from Brainsway, NeoSync, ANS/St. Jude. Equipment support from Magstim, Magventures.

**Malhotra, Anil:** *Part 1:* Genomind

**Mann, J. John:** *Part 2:* Royalties from Research Foundation for Mental Health for C-SSRS, *Part 4:* Unrelated past grants from GSK and Novartis

**March, Mary :** *Part 4:* The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Markou, Athina:** *Part 4:* Bristol-Myers-Squibb.

**Marnett, Lawrence:** *Part 1:* DJH, LJM and SP have submitted a patent application entitled "Compositions and Methods for Substrate-Selective Inhibition of Endocannabinoid Oxygenation," which includes the compound LM-4131.

**Marx, Christine:** *Part 1:* Applicant or co-applicant, pending patents on the use of neurosteroids and derivatives in CNS disorders and for lowering cholesterol (no patents issued, no licensing in place). Unpaid scientific advisor, Sage Therapeutics.

**Mathalon, Daniel:** *Part 1:* Consultant for Amgen, Consultant for BristolMyers Squibb

**Matsumoto, Mickey:** *Part 1:* I am an employee of Astellas Research Institute of America LLC, a subsidiary of Astellas Pharma Inc., *Part 2:* Astellas Research Institute of America LLC., *Part 3:* Astellas Research Institute of America LLC., *Part 5:* Astellas Research Institute of America LLC.

**McCracken, James:** *Part 1:* Research Contracts: Roche, Seaside Therapeutics, Otsuka, Consultant Income: Roche, BioMarin, PharmaNet, Speaker Honoraria: Tourette Syndrome Association, *Part 2:* Research Contracts: Roche, Seaside Therapeutics, *Part 3:* None, *Part 4:*None

**McCullumsmith, Cheryl:** *Part 1:* Jansenn Pharmaceuticals : Suicide Advisory Board

**McGorry, Patrick:** *Part 1:* I have received honoraria for educational and consultancy activities and/or travel support to attend such consultancy meetings from Janssen Cilag, Servier and Roche and unrestricted research grant support from Janssen Cilag and Astra Zeneca, *Part 4:* Unrestricted research grant support from Janssen Cilag and Astra Zeneca

**Meyer-Lindenberg, Andreas:** *Part 1:* Speaker and Advisory boards: AstraZeneca, J+J, Lundbeck, Servier, Lilly

**Miller, Andrew:** *Part 1:* Abbott Laboratories, AstraZeneca, Centocor Inc., GlaxoSmithKline, Lundbeck Research USA, F. Hoffmann-La Roche Ltd., Schering-Plough Research Institute and Wyeth/Pfizer Inc., *Part 4:* Centocor Inc., GlaxoSmithKline, and Schering-Plough Research Institute

**Miyakawa, Tsuyoshi:** *Part 1:* Advisor/Consultant for Astellas Pharma Inc.

**Murrough, James:** *Part 1:* Dr. Murrough has received research support from Janssen Pharmaceuticals and Avanir Pharmaceuticals., *Part 4:* Dr. Murrough has received research support from Janssen Pharmaceuticals and Avanir Pharmaceuticals.

**Nemeroff, Charles:** *Part 1:* Skyland Trail, Cenerx, Novadel Pharma, Takeda, Revaax Pharma, Xhale, Allergan, Lilly, Roche, Shire, SK Pharma, PharmaNeuroboost, *Part 2:* Cenerx, Novadel Pharma, PharmaNeuroboost, Xhale, *Part 3:* Xhale, PharmaNeuroboost, Cenerx, Novadel Pharma

**Nuechterlein, Keith:** *Part 1:* Investigator-Initiated Research Grant from Janssen Scientific Affairs, LLC, Research grant from Brain Plasticity, Inc., Consultant and research grant, Genentech, Consultant, Otsuka, *Part 4:* Investigator-Initiated Research Grant from Janssen Scientific Affairs, LLC, Research grant from Brain Plasticity, Inc., Research grant from Genentech

**Nye, Jeffrey:** *Part 1:* Employee of Janssen/J&J, *Part 2:* Employee of Janssen/J&J, *Part 3:* Employee of Janssen/J&J, *Part 4:* Employee of Janssen/J&J, *Part 5:* Employee of Janssen/J&J

**O'Malley, Stephanie:** *Part 1:* ACTIVE workgroup supported be Eli Lilly, Lundbeck, Alkermes, Pfizer, Johnson and Johnson, GSK, Abbott, Hazelden Foundation, Applied behavior research, Pfizer, *Part 4:* Eli Lilly contract, Pfizer medication supplies

**Patel, Maxine:** *Part 1:* Consultancy: Janssen; Endo; Amgen; Lundbeck, Principal or Chief Investigator for clinical studies: Amgen; Lundbeck, *Part 4:* Principal or Chief Investigator for clinical studies: Amgen; Lundbeck,

**Patel, Sachin:** *Part 1:* DJH, LJM and SP have submitted a patent application entitled "Compositions and Methods for Substrate-Selective Inhibition of Endocannabinoid Oxygenation," which includes the compound LM-4131.

**Paul, Steven:** *Part 1:* Alnylam Pharmaceuticals (Board of Directors), Constellation Pharmaceuticals (Board of Directors), Eli Lilly (Stockholder), Karuna Pharmaceuticals (Board of Directors), Sage Therapeutics (Founder and shareholder), Sigma Aldrich Company (Board of Directors), Tal Medical Pharmaceuticals (Scientific Advisory Board and Board of Directors), Third Rock Ventures (Venture Partner). , *Part 2:* Alnylam Pharmaceuticals (Board of Directors), Constellation Pharmaceuticals (Board of Directors), Eli Lilly (Stockholder), Karuna Pharmaceuticals (Board of Directors), Sage Therapeutics (Founder and shareholder), Sigma Aldrich Company (Board of Directors), Tal Medical Pharmaceuticals (Scientific Advisory Board and Board of Directors), Third Rock Ventures (Venture Partner). , *Part 3:* Alnylam Pharmaceuticals (Board of Directors), Eli Lilly (Stockholder), Sage Therapeutics (Founder and shareholder), Sigma Aldrich Company (Board of Directors), Third Rock Ventures (Venture Partner). , *Part 4:* Alzheimer's Drug Discovery Foundation, AstraZeneca Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Alzheimer's Drug Discovery Foundation, NIH R01 grant.

**Pearlson, Godfrey:** *Part 1:* Consultant BMS 2012

**Pelham, William :** *Part 1:* Gave a talk at a conference in Japan that was sponsored by Janssen Pharmaceuticals

**Perkins, Diana:** *Part 1:* Consultant: Genentech/Roche, Sunovion, Otsuka

**Peterchev, Angel:** *Part 1:* Dr. Peterchev is inventor on patents and patent applications on TMS technology assigned to Columbia University and Duke University, including technology licensed to Rogue Research; was Principal Investigator on a research grant to Duke from Rogue Research and equipment donations to Columbia and Duke by Magstim, MagVenture, and ANS/St. Jude Medical; has received patent royalties from Rogue Research through Columbia for TMS technology; and has received travel support from Rogue Research through Duke., *Part 3:* Dr. Peterchev has received patent royalties from Rogue Research through Columbia University for TMS technology that he invented., *Part 4:* Dr. Peterchev was Principal Investigator on a research grant to Duke from Rogue Research and of equipment donations to Columbia and Duke by Magstim and MagVenture.

**Phillips, Mary:** *Part 2:* I have been a consultant for Cardiff University, Department of Psychological Medicine, UK. This relationship is due to end in 2013.

**Pletcher, Mathew:** *Part 1:* Employee of Pfizer, *Part 5:* Pfizer

**Posner, Kelly :** *Part 1:* Dr. Posner is the director of the Center for Suicide Risk Assessment. The Center, as part of an effort to help execute the FDA suicidality classification mandates, has received support from the following pharmaceutical companies: Abbott, Aerial Biopharma, Albany Molecular Research, Alder Biopharma, Alfresa, Alkermes, Amgen, Astellas Pharm, Astra Zeneca, Biogen, Biomarin Pharmaceutical, Biovail Technologies, Boehringer Ingelheim, Bracket, Bristol Myers Squibb, Cato Research, Celerion, Cephalon, Cetero Research, Chiesi Pharmaceuticals, Covance, CRI Worldwide, Daiichi Sankyo Company, Depomed, Douglas Pharmaceuticals/VersaPharm, EISAI, Elan, EnVivo, Epiomed, Forest, Gilead, GlaxoSmithKline, Grunenthal, GW Pharma Limited, Human Genome Sciences, i3 International, i3 Research, i3 Pharmaceutical Services, ICON Development Solutions, Impax Laboratories, INC Research, Ingenix, IntelGenx Corp, IntraCellular Therapies, Ironwood, IRIS, Isis, Ivax, Janssen, Jazz, Johnson & Johnson, Lilly USA, Lotus, Lundbeck, MedAvante, MedImmune, Merck, Mochida, Neurocrine Biosciences, Neuronex, Neurosearch, NextWave Pharma, Novartis, Noven, NovoNordisk, Omeros, Orexigen Therapeutics, Orion, Otsuka, PamLab, Parexel, Pfizer, PGx Health, Pharmaceutical Research Associates, Pharmanet i3, Pierrel Research, PPD, Prana Biotechnology, ProPhase, Psyadon, QED Pharmaceuticals, Quintiles, Receptos, Reckitt Benckiser, Rho, Rhythm, Roche, Sanofi-Aventis, Schering-Plough, Schwarz Biosciences, SCOPE International, Sepracor, Shionogi, Shire, Siena Biotech, SK Life Science, Sunovion, Supernus Pharmaceuticals, Synosia Therapeutics, Takeda Global Research & Development Center, Takeda Pharmaceuticals, TauRx Therapeutics, Theravance, UCB Biosciences, UCB Korea, UCB Pharma, United BioSource Corp, Upsher-Smith Laboratories, Vaccinex, Valeant Pharmaceuticals, Vernalis, Vivus, WorldWide Clinical Trials, Wyeth Ayerst, Wyeth Pharmaceuticals, Wyeth Research, Xenoport and Zalicus. Dr. Posner receives royalty payments from the e-CSSRS, which are distributed to her by her employer, the Research Foundation for Mental Hygiene.

**Potenza, Marc:** *Part 1:* Consulting to Boehringer-Ingelheim and Lundbeck; financial interests in Somaxon. Grant from Psyadon., *Part 4:* Grant from Psyadon.

**Rauch, Scott:** *Part 1:* 2011 NIMH RDoC - honorarium, 2011 & 2012 - Oxford University Press - royalty, 2011 & 2012 - APPA - royalty, *Part 2:* None other than my primary employer: McLean Hospital/Partners

Healthcare, *Part 3*: None other than my primary employer: McLean Hospital/Partners Healthcare, *Part 4*: Cyberonics, Medtronic

**Ray, Lara:** *Part 1*: I am a paid consultant for GSK.

**Reynolds, Charles:** *Part 1*: none, *Part 2*: I receive an honorarium from the American Association for Geriatric Psychiatry, for service as associate editor of the American Journal of Geriatric Psychiatry, *Part 3*: none, *Part 4*: During the past three years I have received pharmaceutical supplies for my NIH sponsored clinical trials from Pfizer (venlafaxine, aripiprazole, donepezil) and Eli Lilly (duloxetine), *Part 5*: not applicable; primary employer = University of Pittsburgh and UPMC

**Risbrough, Victoria:** *Part 4*: Research grants awarded from Johnson and Johnson, Omeros Pharmaceuticals, Sunovion Pharmaceuticals, and Johnson and Johnson.

**Robbins, Trevor:** *Part 1*: Consultancy: Cambridge Cognition, Lilly, Merck, GlaxoSmithKline, Lundbeck, Teva, Shire Pharmaceuticals, ChemPartners, Royalties: Cambridge Cognition (CANTAB), Editorial Honoraria: Springer Verlag (Psychopharmacology), *Part 2*: Cambridge Cognition, *Part 3*: Cambridge Cognition, *Part 4*: Lilly, Lundbeck, GlaxoSmithKline

**Roffman, Joshua:** *Part 4*: Pamlab

**Rogawski, Michael:** *Part 1*: Marinus Pharmaceuticals, Sage Therapeutics, Eisai, UCB, Upsher-Smith, *Part 2*: University of California, Davis, Sage Therapeutics, *Part 4*: Gilead Sciences, Eisai, UCB

**Ruparel, Kosha:** *Part 4*: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Russo, Scott:** *Part 4*: Dr Russo receives laboratory support from Johnson and Johnson to study IL-6 and depression.

**Sablinski, Tomasz:** *Part 5*: Auen Therapeutics, Transpartency Life Sciences

**Sahakian, Barbara:** *Part 1*: Cambridge Cognition Limited, Lundbeck, Janssen/ J&J, Roche, *Part 2*: Cambridge Cognition Limited, *Part 4*: Janssen/J&J, Foresight, BIS, Government Office for Science

**Sanchez, Raymond :** *Part 1*: Employee of Otsuka Pharmaceutical Development and Commercialization (Vice President, Global Clinical Development CNS), *Part 2*: Employee of Otsuka Pharmaceutical Development and Commercialization, *Part 5*: Otsuka Pharmaceutical Development and Commercialization

**Satterthwaite, Theodore:** *Part 4*: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Sawa, Akira:** *Part 4*: Research Support:, Astellas Pharm., Dainippon Sumitomo, Mitsubishi-Tanabe Pharm., Takeda, Johnson and Johnson, Consultant:, Pfizer, Asubio, Sucampo, Eli Lilly, Taisho,



Collaboration:, Pfizer, Afraxis, Astellas Pharm., Dainippon Sumitomo, Mitsubishi-Tanabe Pharm., Takeda, Sanofis-Avenis, Johnson and Johnson

**Schadt, Eric:** *Part 1:* SAB for Pacific Biosciences and SAB for Berg, *Part 2:* SAB for Pacific Biosciences and SAB for Berg.

**Schork, Nicholas:** *Part 1:* Dr. Schork is a founder of CypherGenomics (<http://www.cyphergenomics.com/>) and on the board of MD Revolution (<http://mdrevolution.com/>) and has stock as a result.

**Sheehan, David:** *Part 1:* Advisory Board membership to Roche, Sagene Pharma, Otsuka, Forest, Novadel, Labopharm, Neuronetics, International Society for CNS Drug Development (ISCDD). Consultant to Sagene Pharma, Janssen (JNJ), MAPI, Prime Education, Neuronetics, ProPhase, Novadel, xCenda, Targacept, PharmaNeuroBoost. Payments for lectures from Pfizer, Eli Lilly, Glaxo, LaboPharm Angelini, Merck, PharmaNeuroBoost, Quintiles, Hikma, United BioSource, Janssen (JNJ), IncResearch, Otsuka. Payment for manuscript preparation from Quadrant HealthCom Inc. Royalties from eResearch Technology, Pfizer and Simon and Schuster. Stock in Medical Outcomes Systems. Travel Expenses to two ISCDD meetings paid by ISCDD., *Part 2:* Sagene Pharma, Labopharm, Neuronetics, MAPI, Pfizer, Eli Lilly, Glaxo.

**Shelton, Richard:** *Part 1:* Bristol-Myers Squibb, Cyberonics, Inc., Elan, Corp., Eli Lilly and Company, Euthymics Bioscience, Forest Pharmaceuticals, Janssen Pharmaceutica, Medtronic, Inc., Naurex, Inc., Novartis Pharmaceuticals, Otsuka Pharmaceuticals, Pamlab, Inc., Pfizer, Inc., Repligen, Corp., Ridge Diagnostics, St. Jude Medical, Inc., Takeda Pharmaceuticals, *Part 2:* Pamlab, Inc., *Part 4:* Bristol-Myers Squibb, Elan, Corp., Eli Lilly and Company, Euthymics Bioscience, Forest Pharmaceuticals, Janssen Pharmaceutica, Naurex, Inc., Novartis Pharmaceuticals, Otsuka Pharmaceuticals, Pamlab, Inc., Repligen, Corp., Ridge Diagnostics, St. Jude Medical, Inc., Takeda Pharmaceuticals

**Simpson, Helen:** *Part 1:* Consultation for Quintiles, Inc. (on therapeutic needs for OCD), 9/2012, *Part 4:* Research support from Transcept Pharmaceuticals for ondansetron study 2011-2013, Research support for medication at no-cost from Janssen Pharmaceuticals 2006-2012 for NIMH funded study in OCD

**Smith, Mark:** *Part 5:* Former employee of AstraZeneca Pharmaceuticals in Wilmington DE, the company that funded/sponsored the study reported here. , Current employee of Shire Pharmaceuticals in Wayne, PA.

**Stein, Murray:** *Part 1:* Care Management Technologies (Consultant), Up-to-Date (Co-Editor-in-Chief, Psychiatry), Depression and Anxiety [Wiley] (Associate Editor), *Part 2:* University of California San Diego, Va San Diego Healthcare System, Up-To-Date, *Part 3:* Up-To-Date, *Part 4:* Janssen (Co-Investigator on Research Contract)

**Stephens, David:** *Part 1:* Research Contract with GSK, Cambridge, UK, Consultant with Merz & Co, Frankfurt, Germany, *Part 2:* Research Contract with GSK, Cambridge, UK

**Svensson, Torgny:** *Part 1:* Consultant/advisory board: AstraZeneca, Janssen, Lundbeck, Otsuka, Merck Sharp and Dome. , *Part 4:* The Swedish Research Council, The Karolinska Institutet, Stockholm (Sweden), The Brain Foundation (Sweden), AstraZeneca, Organon, Schering-Plough, Merck Sharp and Dome, Lundbeck, Otsuka, Astellas

**Swanson, James:** *Part 1:* I have been a consultant with Noven Pharmaceuticals and BLK Pharma, and I received indirect support from pharmaceutical companies from a professional organization, the European Network of Hyperkinetic Disorders (EUNETHYDIS), to make presentations at annual meetings.

**Sweeney, John:** *Part 1:* Consultant to Lilly, Takeda, Roche and BMS

**Swift, Robert:** *Part 1:* Consultant to Transcept Pharmaceuticals - received fee, Scientific Advisory Board for D&A Pharma - received honorarium and travel expenses to meeting, Consultant to Pharmaceutico CT - received fee and travel expense reimbursement, *Part 2:* Consultant to Pharmaceutico CT - fee and travel expense reimbursement

**Tamminga, Carol:** *Part 1:* Astellas; Eli Lilly; Intra-Cellular Therapies; Kaye Scholer LLP; Lundbeck; PureTech Ventures; NIMH; Am J Psychiatry; , *Part 2:* Am J Psychiatry; KayeScholer LLP; IntraCellular Therapies, *Part 4:* Sunovion

**Thomas, Jason:** *Part 1:* PhD studentship part funded by P1vital, *Part 3:* PhD studentship part funded by P1vital, *Part 4:* PhD studentship part funded by P1vital

**Trivedi, Madhukar:** *Part 1:* Madhukar H. Trivedi is or has been an advisor/consultant to, Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, GlaxoSmithKline, Janssen Global Services, LLC, Janssen Pharmaceutica Products, LP, Johnson & Johnson PRD, Lundbeck, MedAvante, Medtronic, Merck, Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Pfizer Inc., Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd., Sepracor, SHIRE Development, Sierra, Sunovion, Takeda, Targacept, Transcept, and Wyeth-Ayerst Laboratories., *Part 4:* Dr. Trivedi has received research support from: Agency for Healthcare Research and Quality (AHRQ), National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse.

**Turetsky, Bruce:** *Part 4:* The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Uchida, Hiroyuki:** *Part 1:* Dr. Uchida has received speaker's honoraria from Otsuka Pharmaceutical, Janssen Pharmaceutical, Novartis Pharma, Eli Lilly, Shionogi, GlaxoSmithKline, Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, and Janssen Pharmaceutical within the past two years. , *Part 4:* Dr. Uchida has received grants from Pfizer, Astellas Pharmaceutical, Eisai, Otsuka Pharmaceutical, GlaxoSmithKline, Shionogi, and Dainippon-Sumitomo Pharma, Eli Lilly, Mochida Pharmaceutical, Meiji-Seika Pharma, Janssen Pharmaceutical, and Yoshitomi Yakuhin within the past two years.

**Uher, Rudolf:** *Part 1:* Dr Uher co-chairs a steering board of a research project initiated and funded by Bristol Myers Squibb and collaborates with Pfizer, Glaxo-Smith Kline and Roche as part of the European

Union Innovative Medicine Initiative funded NEWMEDS project. Dr Uher has received no personal income from any pharmaceutical or biotech industry and holds no equity in companies active in medicine, pharmaceuticals or biotechnology.

**Van Zeeland, Ashley:** *Part 1:* Dr. Van Zeeland is a Co-founder and CEO of CypherGenomics (<http://www.cyphergenomics.com/>) and has stock as a result., *Part 5:* Cypher Genomics

**Vinogradov, Sophia:** *Part 1:* consultant to BrainPlasticity Institute

**Wahlestedt, Claes:** *Part 1:* Pfizer, OPKO

**Walker, Brendan:** *Part 4:* Completed a cooperative research agreement on 9/24/2011 with H. Lundbeck A/S, Copenhagen on the kappa-opioid mechanisms of nalmefene.

**Warden, Melissa:** *Part 1:* Stanford University has filed for patent protection on technology invented by Dr. Melissa R. Warden and Dr. Karl Deisseroth.

**Waxmonsky, James:** *Part 1:* Research Contract Noven Pharmaceuticals, Research Contract Janssen, Research Contract Shire Inc. , Advisory Board Noven Pharmaceuticals (<\$5,000), *Part 4:* Research Contract Noven Pharmaceuticals, Research Contract Janssen, Research Contract Shire Inc.

**Wigal, Tim:** *Part 1:* Otsuka and McNeil, *Part 4:* Eli Lilly, Noven, Shire and Rhodes Pharamceuticals

**Wing, Victoria:** *Part 4:* Pfizer IIR Operating Grant 2012-2014 (\$50,000), Pfizer IIR 2010-2013 (medication supply only), Pfizer GRAND Operating Grant 2013-2015 (\$20,000)

**Winterer, Georg:** *Part 1:* Pharmalmage - Biomarker Solutions GmbH (CEO), Janssen Pharmaceutica (consulting, services) , Lundbeck (consulting, services), Boehringer Ingelheim (consulting), UCB Pharma (consulting, services), Pfizer (speaker bureau, grant), Focus Drug Development (consulting, services), Dritte Patent Portfolio Beteiligungsgesellschaft mbH & Co KG (consulting), Ratiopharm (consulting), *Part 2:* Pharmalmage - Biomarker Solutions GmbH (CEO), Janssen Pharmaceutica (consulting, services) , Lundbeck (consulting, services), UCB Pharma (consulting, services), Focus Drug Development (consulting, services), *Part 3:* Pharmalmage - Biomarker Solutions GmbH (CEO), Janssen Pharmaceutica (consulting, services) , Lundbeck (consulting, services), Focus Drug Development (consulting, services), *Part 4:* Pfizer/McNeill

**Wolf, Daniel:** *Part 4:* The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Wolf, Marina:** *Part 1:* I have 50,000 shares (~\$50,000) in a non-publicly traded entity: Grace Laboratories LLC, 1755 Logans Knoll NE, Atlanta GA 30329. I do not receive any income at this time. There is no linkage to my research or to ACNP., I have 50,000 shares (~\$50,000) in a non-publicly traded entity: CIS Blotech Inc, 2701 North Decatur Rd, Decatur, GA 30033. I do not receive any income at this time. There is no linkage to my research or to ACNP., *Part 2:* I have 50,000 shares (~\$50,000) in a non-publicly traded entity: Grace Laboratories LLC, 1755 Logans Knoll NE, Atlanta GA 30329. I do not receive any income at

this time. There is no linkage to my research or to ACNP., I have 50,000 shares (~\$50,000) in a non-publicly traded entity: CIS Blotech Inc, 2701 North Decatur Rd, Decatur, GA 30033. I do not receive any income at this time. There is no linkage to my research or to ACNP.

**Wong, Dean:** *Part 1:* Consultant for Amgen and Concert Pharmaceuticals, *Part 2:* Johns Hopkins University, School of Medicine, *Part 4:* Avid, Biotie, GE, Intracellular, J+J, Lilly, Lundbeck, Merck, NIH, Otsuka, Roche, Sanofi-Aventis, Synosia

**Woods, Scott:** *Part 1:* Investigator-initiated grant from Pfizer, *Part 4:* Investigator-initiated grant from Pfizer

**Yates III, John R.:** *Part 1:* ThermoFisher, *Part 2:* ThermoFisher, *Part 4:* Roche

**Youngstrom, Eric:** *Part 1:* Eric Youngstrom has consulted with Lundbeck and received past travel support from Bristol-Myers Squibb. He has consulted with Penn State about analyses for a grant funded by Pfizer, and received grant funding from NIMH.

**Zarate, Carlos:** *Part 1:* Dr. Zarate is listed as a co-inventor on a patent application for the use of ketamine and its metabolites in major depression. Dr. Zarate has assigned his rights in the patent to the U.S. government but will share a percentage of any royalties that may be received by the government.

**Zhang, H. Steve:** *Part 5:* Sangamo Biosciences

**Zorumski, Charles:** *Part 1:* I serve on the Scientific Advisory Board of Sage Therapeutics., *Part 2:* .

**Zukin, Stephen:** *Part 5:* Former employee of AstraZeneca Pharmaceuticals in Wilmington DE, the company that funded/sponsored the study reported here., Current employee of Forest Research Institute in Jersey City, New Jersey.

Following Faculty Had Nothing to Disclosure:

Dean Acheson  
Jean Addington  
Susanne Ahmari  
Schahram Akbarian  
Martin Alda  
Ream Al-Hasani  
Susan Amara  
Mala Ananth  
Katrin Arelin  
Peter Bachman  
Dewleen Baker  
Tracy Bale  
Ruben Baler

Elizabeth Balough  
Michael Baumann  
Jaime Becnel  
Gillinder Bedi  
Odetta Beggel  
Aysenil Belger  
Sabina Berretta  
Wade Berrettini  
Timothy Bestor  
Bruno Biagiante  
James Bibb  
Elisabeth Binder  
James Bjork  
Jeffrey Borckardt  
Jake Bosin  
Jennifer Bossert  
Kathleen Brady  
Linda Brady  
Jess Brallier  
Timothy W. Bredy  
Truman Brown  
Michael Bruchas  
Han Brunner  
Katherine Burdick  
Inga Burmann  
Meryl Butters  
Dan Buysse  
Kristin Cadenhead  
Catherine Cahill  
Tyrone Cannon  
Melanie Canterbury  
Nicole Capik  
Facundo Carillo  
Marlene Carlson  
Ricardo Carrion  
Hannah Cates  
Guillermo Cecchi  
Moses Chao  
Joseph Cheer  
Alon Chen  
Brandon Chuang  
Toni-Kim Clarke  
Paula Clayton  
Brett Clementz  
Christine Colvis  
Wilson Compton  
Mark Connelly  
Robin Cooper

Cheryl Corcoran  
Barbara Cornblatt  
Kathryn Cunningham  
Megan Davis  
Michael De Bellis  
Jacek Debiec  
Karl Deisseroth  
Mauricio Delgado  
Christine Denny  
Pamela DeRosse  
Jordan DeVlyder  
Brian Dias  
Elisa Dias  
Jesse Dills  
Yan Dong  
Glenn Doyle  
Liam Drew  
Manoranjan D'Souza  
Elizabeth Duval  
John Edwards  
Igor Elman  
Mark Emmett  
Heather Eng  
Michael Epstein  
Monique Ernst  
Emad Eskandar  
Irina Esterlis  
Amit Etkin  
Gary Evans  
Jennifer Felger  
Deveroux Ferguson  
Russell Ferland  
Diego Fernandez Slezak  
Francesca Filbey  
Erika Forbes  
Audra Foshage  
Joanna Fowler  
Andrew Fox  
Nathan Fox  
Paul Frankland  
Joseph Friedman  
Henn Fritz  
Flavio Frohlich  
Brian Frosh  
Julie Fudge  
Dan Fulford  
Chris Fussell  
Aurelio Galli

Joyonna Gamble-George  
Sarah Garfinkel  
Xiujuan Geng  
Mark George  
Susan George  
Vincent Giguere  
John Gilmore  
Jay Gingrich  
Santhosh Girirajan  
Nitin Gogtay  
Rita Goldstein  
Raul Gonzalez  
David Grandy  
Kathleen Grant  
Steven Grant  
Rachel Greene  
Nuria Gresa-Arribas  
Amanda Guyer  
Victoria Haghighi  
Maureen Hahn  
Tomas Hajek  
Batsheva Halberstam  
Katherine Ann Halmi  
Ahmad Hameed  
Robert Hamer  
Bruce D. Hammock  
Colleen Hanlon  
Nolan Hartley  
Karen Hartwell  
Elizabeth Heller  
J. Dee Higley  
Noboru Hiroi  
Georgia Hodes  
Rachel Hodge  
Daniel Hong  
Hailan Hu  
Thomas Hyde  
Thomas Insel  
Michael Irwin  
Koko Ishizuka  
Jacob Jacobsen  
Andrew Jaffe  
J. David Jentsch  
Jarcho Johanna  
Jason Johannesen  
Oralee Johnson  
Sara Jones  
Sheena Josselyn

Peter Kalivas  
Yeona Kang  
Thomas Kash  
Siegfried Kasper  
Walter Kaye  
Matthew Kayser  
Edmund Kerut  
Matcheri Keshavan  
Mazen Kheirbek  
Janice Kiecolt-Glaser  
Dohyun Kim  
Ronald Kim  
Sung Won Kim  
Jonathan Kipnis  
Robin Kleiman  
Joel Kleinman  
Torsten Klengel  
Rebecca Knickmeyer  
Harold Koenigsberg  
David Kokel  
Genevieve Konopka  
George Koob  
Michael Krashes  
Annegret Krause-Utz  
Adrienne Lahti  
Wanda Lai  
Olivia Lam  
Salomon Langer  
Ruth Lanius  
Janine LaSalle  
Hilde Lavreysen  
Francis Lee  
Thomas Lehner  
Ellen Leibenluft  
Todd LeMatty  
Bernard Lerer  
Marc Lerner  
David Leung  
Cara Levitch  
Kun Li  
Xingbao Li  
Lujian Liao  
Israel Liberzon  
Gregory Light  
Kelvin Lim  
Ryan Logan  
Falk Lohoff  
Edythe London



Miguel Lopez-Teledono  
Francis Lotrich  
David Lovinger  
Bradford Lowell  
Bai Lu  
Bruce Luber  
Farah Lubin  
Alice Luo Clayton  
James Luther  
Angus MacDonald  
Pierre Magistretti  
Zana Majeed  
Roberto Malinow  
Daniel Margulies  
Sander Markx  
Charles Marmar  
Rachel Marsh  
Keri Martinowich  
Jordan McCall  
Colleen McClung  
Robert McCullumsmith  
Christopher McDougle  
Bruce McEwen  
Jacqueline McGinty  
Vinod Menon  
Valentina Mercaldo  
Kathleen Merikangas  
Roger Meyer  
Klaus Miczek  
Arthur Mikhno  
Mohammed Milad  
Maria Milekic  
Brooke Miller  
Gregory Miller  
James Moeller  
Bita Moghaddam  
Suman Mohanty  
Megan Moran-Santa Maria  
Christophe Morisseau  
Sarah Morimoto  
Matthew Mosconi  
Felix Muchomba  
Karim Nader  
Kazuhiko Nakamura  
Sneha Narasimhan  
Eric Nelson  
Eric Nestler  
Thomas Neylan

Charles Nichols  
Philip Nielsen  
Caroline Nievergelt  
Carol Nilsson  
Margaret Niznikiewicz  
Antonio Noronha  
Aoife O'Donovan  
Kevin Ochsner  
Anne O'Donnell  
Michele Okun  
Max Owens  
Angela Ozburn  
Andre Pampel  
Carlos Pardo  
Puja Parekh  
Michael Parides  
Ramin Parsey  
Paul Patterson  
Tomas Paus  
Catherine Pena  
Andrew Perez  
M. Mercedes Perez-Rodriguez  
Phillip Phan  
Marina Picciotto  
David Pickar  
Daniel Pine  
James Prisciandaro  
Gregory Quirk  
Ralf Regenthal  
Kerry Ressler  
Stephan Ripke  
Oliver Robinson  
Stephanie Rohrig  
Jerrold Rosenbaum  
Bryan Roth  
Richard Rothman  
Laura Rowland  
Andrey Rzhetsky  
Julia Sacher  
Michael Saladin  
Derya Sargin  
Nayla Scaramello  
Alexander Schäfer  
Christian Schmahl  
Lauren Schmitt  
Blessan Sebastian  
Larry Seidman  
Barry Setlow

Carla Shatz  
Tomer Shechner  
Pei-an Betty Shih  
Sarah Short  
David Shurtleff  
Larry Siever  
Mariano Sigman  
Gail Silipo  
Jogender Singh Tushir  
Dorothy Sit  
Phil Skolnick  
Vikaas Sohal  
Laili Soleimani  
Nadia Solowij  
Chandra Sripada  
Beth Stevens  
Camilla Stoltenberg  
Scott Stroup  
Garret Stuber  
Regina Sullivan  
Haosheng Sun  
Lawrence Sung  
Ezra Susser  
James Swain  
Jonathan Sweedler  
Peter Szatmari  
Philip Szeszko  
Karen Szumlinski  
Michael Taffe  
Joseph Taylor  
Panayotis Thanos  
Paul Thompson  
Wesley Thompson  
Maarten Titulaer  
Vi Tran  
Gina Turrigiano  
David Vaillancourt  
Edwin van den Oord  
Ashlee Van't Veer  
Joris Veltman  
Eric Vermetten  
Arno Villringer  
Susanna Visser  
Aristotle Voineskos  
Nora Volkow  
Mark Von Zastrow  
Terry Vrijenhoek  
Elaine Walker

Ken Warren  
Christopher Watkins  
Daniel Weinberger  
Anne West  
Douglas Williamson  
Katherine Wisner  
Stephen Wisniewski  
Catherine Wong  
Marcelo Wood  
Josh Woolley  
Sandra Woolson  
Yurong Xin  
Jun Yang  
Zhongfei Yang  
Rachel Yehuda  
Soojin Yi  
Adelaide Yiu  
Bangning Yu  
Deborah Yurgelun-Todd  
Kate Yurgil  
Andrew Zalesky  
Zane Zeier  
Tai Zhou  
Xianjin Zhou

Following Faculty Had No Disclosures:

Amy Arnsten  
David Bredt  
Z. Josh Huang  
Linda Porrino  
Carla Shatz  
John Talpos  
Gina Turrigiano